This is a paid press release. Contact the press release distributor directly with any inquiries.
Elysium Health™ Research Demonstrates Improvements in Menopause Symptoms and Estrogen Balance with Basis™ and Reveals New Insights into NAD+ Metabolism
PR Newswire
Thu, July 9, 2026 at 6:05 PM GMT+5:30
5 min read
Findings demonstrate significant improvements in major disruptive menopausal symptoms and a beneficial increase in E2/E1 ratio
NEW YORK, July 9, 2026 /PRNewswire/ — Elysium Health, Inc.™, the leading longevity science company, today announced new research published in Frontiers in Aging demonstrating significant improvements in disruptive menopausal symptoms in women taking Basis™, the company’s flagship product clinically proven to raise NAD+ levels. The study also showed a significant increase in the ratio of estradiol (E2) to estrone (E1)—two key forms of estrogen—restoring it to a more favorable balance. Lastly, the study characterized a previously unreported NAD+ metabolite, providing new insights into NAD+ metabolism and utilization. To help advance Elysium’s work in the underserved area of women’s health, the company also announced the addition of Yousin Suh, Ph.D., Charles and Marie Robertson Professor of Reproductive Sciences in Obstetrics and Gynecology and Professor of Genetics and Development, and Director of the Reproductive Aging Program at the Vagelos College of Physicians and Surgeons at Columbia University, to its esteemed Scientific Advisory Board.
The open-label pilot study evaluated 40 healthy women over 35 years of age, 32 of which self-reported symptoms associated with the menopause transition (MS group) and eight women who were not experiencing any (or minimal) symptoms associated with menopause (No-MS group). After seven days of Basis supplementation, participants in the MS group self-reported significant reductions—by 50% or more—in the frequency and severity of several of the most disruptive menopause symptoms, including hot flashes, bloating, and poor sleep. While symptom improvement represents an important outcome for women navigating the menopause transition, researchers believe the biological findings may have broader implications for understanding the relationship between estrogen regulation and cellular metabolism.
“This study stemmed from my own experience with Basis helping with menopausal symptoms,” said Marie Migaud, Ph.D., study co-author, longtime Elysium Health research collaborator, and Brian Metcalf Chair in Chemical Biology at The University of Western Australia. “From that experience we hypothesized that supporting NAD+ metabolism could help promote a healthier balance between estradiol and estrone during menopause. We were encouraged to see improvements in estradiol-to-estrone ratios alongside meaningful reductions in the frequency and severity of menopausal symptoms reported by participants. Unexpectedly, the study also led to the discovery of a previously unreported NAD+ metabolite, highlighting how much remains to be learned about NAD+ biology and opening new avenues for future research.”
